Novo Nordisk A/S is a drug manufacturers - general business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $105.06 – an increase of 5.26% over the previous week. Novo Nordisk A/S employs 71,880 staff and has a trailing 12-month revenue of around $270.6 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $105.06 |
|---|---|
| 52-week range | $93.70 - $147.59 |
| 50-day moving average | $118.58 |
| 200-day moving average | $128.19 |
| Wall St. target price | $941.31 |
| PE ratio | 34.0268 |
| Dividend yield | $9.9 (1.42%) |
| Earnings per share (TTM) | $2.99 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $105.06 from 2024-11-22
| 1 week (2024-11-19) | 2.37% |
|---|---|
| 1 month (2024-10-25) | -7.34% |
| 3 months (2024-08-26) | -22.35% |
| 6 months (2024-05-24) | -22.77% |
| 1 year (2023-11-24) | -0.37% |
|---|---|
| 2 years (2022-11-25) | 81.11% |
| 3 years (2021-11-26) | 101.85% |
| 5 years (2019-11-26) | 304.49% |
Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Novo Nordisk A/S shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5387. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novo Nordisk A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $127.4 billion.
The EBITDA is a measure of a Novo Nordisk A/S's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $270.6 billion |
|---|---|
| Operating margin TTM | 47.43% |
| Gross profit TTM | $148.5 billion |
| Return on assets TTM | 21.47% |
| Return on equity TTM | 88.73% |
| Profit margin | 35.01% |
| Book value | $27.07 |
| Market Capitalization | $472.8 billion |
TTM: trailing 12 months
Dividend payout ratio: 46.55% of net profits
Recently Novo Nordisk A/S has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $9.9 per share.
While Novo Nordisk A/S's payout ratio might seem fairly standard, it's worth remembering that Novo Nordisk A/S may be investing much of the rest of its net profits in future growth.
Novo Nordisk A/S's most recent dividend payout was on 25 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 15 August 2024 (the "ex-dividend date").
Novo Nordisk A/S's shares were split on a 2:1 basis on 19 September 2023 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.
Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $93.6985 up to $147.5933. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.165. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.